🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

    phase 2 small molecule active

    1 trial

  2. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  3. MPH966

    Mereo BioPharma Group plc

    Hematologic Malignancy

    phase 2 small molecule terminated

    1 trial

  4. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule active

    1 trial

  5. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  6. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  7. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  8. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  9. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  10. Medical Collagen Membrane with MSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Wounds

    phase 2 other active

    1 trial

  11. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, DANICOPAN, Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    Lacuna Pharma Pty Ltd

    Chronic spontaneous urticaria

    phase 2 small molecule active

    1 trial

  12. Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)

    BRIGHT MINDS BIOSCIENCES INC.

    Meningitis

    phase 2 mab active

    1 trial

  13. Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  14. Metronidazole 500 mg / 100 ml Intravenous Infusion, Metronidazole 500mg/100ml Solution for Infusion, Aztreonam and Avibactam (1.5g/0.5g) Powder for Concentrate for Solution for Infusion, Metronidazole

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  15. Mirikizumab - Intravenous (IV)

    Eli Lilly and Company

    Colitis, Ulcerative

    phase 2 small molecule active

    1 trial

  16. MoLuoDan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Precancerous Condition

    phase 2 small molecule active

    1 trial

  17. Mood Management Phone Counseling for Smoking Cessation

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking

    phase 2 other completed

    1 trial

  18. Mosunetuzumab

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  19. NAL ER

    Trevi Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  20. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule terminated

    4 trials

  21. NK cell perfusion group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Abortion, Missed

    phase 2 mab active

    1 trial

  22. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  23. NOE-105, Placebo, Hard Capsules

    Lacuna Pharma Pty Ltd

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  24. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources